Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?

被引:19
作者
Bilici, Ahmet [1 ,2 ]
Ustaalioglu, Bala Basak Oven [2 ]
Ercan, Serif [3 ]
Orcun, Asuman [3 ]
Seker, Mesut [2 ]
Salepci, Taflan [2 ]
Gumus, Mahmut [2 ]
机构
[1] Menderes Mah, TR-34210 Istanbul, Turkey
[2] Dr Lutfi Kirdar Kartal Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey
[3] Dr Lutfi Kirdar Kartal Educ & Res Hosp, Dept Biochem, Istanbul, Turkey
关键词
Plasma M30 level; Plasma M65 levels; Gastric cancer; Survival; CASPASE-CLEAVED CYTOKERATIN-18; CELL-DEATH; LUNG-CANCER; APOPTOSIS; SERUM; CHEMOTHERAPY; BIOMARKERS; PROGNOSIS; PRODUCT; TUMOR;
D O I
10.1007/s00280-010-1480-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
M30 and M65 are different circulating fragments of cytokeratin 18. They release during apoptotic cell death, so it is believed that they reflect cell death of epithelial tumors. The aim of this study was to determine the prognostic value of plasma M30 and M65 levels in predicting of survival for patients with advanced gastric cancer compare with healthy controls. Thirty-four patients with advanced gastric cancer and thirty-two healthy controls were included. Plasma M30 and M65 values were measured by quantitative ELISA method. The median age of patients and control groups was 60 and 56 years, respectively. No difference was detected between patient and control groups with respect to plasma median M30 values (390.4 vs. 270.7 U/l, respectively, P = 0.10). The median plasma M65 values of patients were significantly higher than those of control group (1232.1 vs. 580.1 U/l, P < 0.001). The best cut-off values for plasma M30 and M65 for predicting progression-free survival (PFS) were 277.7 and 1434.9 U/l in ROC analysis. The patients whose plasma M30 values were higher than 277.7 U/l had worse PFS than patients with plasma M30 value < 277.7 U/l (8.9 vs. 11.2, respectively, P = 0.01). The median PFS of patients whose M65 levels lower than or equal to 1434.9 U/l was better than that of patients whose M65 levels were > 1434.9 U/l (12.4 vs. 10.4, respectively, P = 0.04). But plasma M30 and M65 level in patient group were not found to be an important prognostic factor for PFS in the multivariate analysis. These results showed that plasma M65 values were significantly elevated in patients with advanced gastric cancer compared to healthy people. Moreover, both increased plasma M30 and M65 levels can predict PFS in patients with gastric cancer.
引用
收藏
页码:309 / 316
页数:8
相关论文
共 50 条
[41]   Evening cortisol levels are prognostic for progression-free survival in a prospective pilot study of head and neck cancer patients [J].
Cash, Elizabeth ;
Beck, Isak ;
Harbison, Brooks ;
Albert, Christy ;
Sephton, Sandra E. .
FRONTIERS IN ONCOLOGY, 2024, 14
[42]   Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer [J].
Zimmer, Philipp ;
Esser, Tobias ;
Lueftner, Diana ;
Schuetz, Florian ;
Baumann, Freerk T. ;
Rody, Achim ;
Schneeweiss, Andreas ;
Hartkopf, Andreas D. ;
Decker, Thomas ;
Uleer, Christoph ;
Stoetzer, Oliver J. ;
Foerster, Frank ;
Schmidt, Marcus ;
Mundhenke, Christoph ;
Steindorf, Karen ;
Tesch, Hans ;
Jackisch, Christian ;
Fischer, Thomas ;
Hanson, Sven ;
Kreuzeder, Julia ;
Guderian, Gernot ;
Fasching, Peter A. ;
Bloch, Wilhelm .
BMC MEDICINE, 2024, 22 (01)
[43]   Impact of Vitamin D Levels on Progression-Free Survival and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Systematic Review and Meta-Analysis [J].
Ottaiano, Alessandro ;
Facchini, Bianca Arianna ;
Iacovino, Marialucia ;
Santorsola, Mariachiara ;
Facchini, Sergio ;
Di Mauro, Giordana ;
Toscano, Enrica ;
Montopoli, Monica ;
Di Mauro, Annabella ;
Quagliariello, Vincenzo ;
Maurea, Nicola ;
Vanni, Gianluca ;
Bignucolo, Alessia ;
Montella, Liliana ;
Materazzo, Marco ;
Roselli, Mario ;
Buonomo, Oreste Claudio ;
Berretta, Massimiliano .
CANCERS, 2024, 16 (24)
[44]   Association Between Hormonal Maintenance Therapy and Progression-Free Survival in Advanced Epithelial Ovarian Cancer Patients: A Retrospective Study [J].
Sadeghi, Alireza ;
Torki, Mehdi ;
Ashrafi, Farzaneh ;
Akbari, Mojtaba ;
Pourajam, Samaneh .
INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 22 (02)
[45]   Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer [J].
Wang, Ning-Fang ;
Tang, Hong-Mei ;
Liu, Fang-Lei ;
Hong, Qun-Ying .
CHINESE MEDICAL JOURNAL, 2020, 133 (07) :786-791
[46]   Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer [J].
Wang NingFang ;
Tang HongMei ;
Liu FangLei ;
Hong QunYing .
中华医学杂志英文版, 2020, 133 (07) :786-791
[47]   The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer A Systematic Review and Qualitative Assessment of the Literature [J].
Raphael, Michael J. ;
Robinson, Andrew ;
Booth, Christopher M. ;
O'Donnell, Jennifer ;
Palmer, Michael ;
Eisenhauer, Elizabeth ;
Brundage, Michael .
JAMA ONCOLOGY, 2019, 5 (12) :1779-1789
[48]   Re: Beta Blockers and Improved Progression-Free Survival in Patients With Advanced HER2 Negative Breast Cancer Response [J].
Spera, Gonzalo ;
Fresco, Rodrigo ;
Fung, Helena ;
Mackey, John R. .
EPIDEMIOLOGY, 2018, 29 (05) :E40-E40
[49]   Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors [J].
Iivanainen, Sanna ;
Ahvonen, Jarkko ;
Knuuttila, Aija ;
Tiainen, Satu ;
Koivunen, Jussi Pekka .
ESMO OPEN, 2019, 4 (04)
[50]   The Clinical Impact of Combining Neutrophil-to-Lymphocyte Ratio with Sarcopenia for Improved Discrimination of Progression-Free Survival in Patients with Colorectal Cancer [J].
Lee, Su Young ;
Chung, Eric ;
Cho, Eun-Suk ;
Lee, Jae-Hoon ;
Park, Eun Jung ;
Shin, Su-Jin ;
Baik, Seung Hyuk ;
Lee, Kang Young ;
Kang, Jeonghyun .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (02)